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Available online xxxxBackground:We hypothesized that a reversal of the physiological stiffness gradient, previously reported in end-
stage renal disease, begins in the early stages of chronic kidney disease (CKD) and that chronic inﬂammation pro-
duces a different arterial phenotype in patients with ulcerative colitis (UC).
Objectives: To assess the extent of arterial stiffening in the central (carotid-femoral pulse wave velocity, cf.-PWV)
and peripheral arteries (carotid-radial pulse wave velocity, cr-PWV) and to explore the determinants of the stiff-
ness gradient in UC and in CKD.
Methods:We enrolled 45 patients with UC, 45 patients with stage 3–4 CKD and 45 matched controls.
Results:Despite the comparable cf.-PWV, the cr-PWVwas higher in patientswithUC than in thosewith CKD (me-
dian: 8.7 vs. 7.5m/s; p b 0.001) and, consequently, the PWV ratiowas lower (median: 0.97 vs. 1.12; p b 0.001). In
patients with CKD a stiffness mismatch was reported starting from stage 3B. The PWV ratio was associated with
age and C-reactive protein (beta: 0.08 z-score, 95%CI 0.02–0.14; p= 0.01) or active disease (beta: 0.43 z-score,
95%CI 0.003–0.857; p= 0.048) in patients with UC and with age and glomerular ﬁltration rate (beta:−0.56 z-
score, 95%CI−1.05 to−0.07; p= 0.02) in patients with CKD.
Conclusions: The arterial phenotype differed between UC and CKD. The reversal of the arterial stiffness gradient is
evident in CKD patients starting from stage 3B but not in patients with UC and comparable cf.-PWV. In patients
with UC, the stiffness of both elastic and muscular arteries is increased as a consequence of inﬂammation.
© 2017 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.Keywords:
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Cardiovascular disease is the leading cause of mortality in patients
with chronic kidney disease (CKD). This high rate ofmortality is partial-
ly explained by an increase in aortic stiffness [1]. In young adults, the
aorta is considerably more elastic than peripheral muscular arteriesugmentation index; Anti-TNF,
se wave velocity; CKD, chronic
; DBP, diastolic blood pressure;
MBP, mean blood pressure; PP,
e colitis.
of Nephrology, Department of
tario, University of Catania, Via
spedale “San Bassiano”, 36061
.lentini@yahoo.it (P. Lentini).
cine. Published by Elsevier B.V. All rig
wave velocity differs betweenand provides a physiological stiffness gradient that leads to a partial re-
ﬂection of the advancing pressure wave and dampens the transmission
of forward traveling pressure into the microcirculation. During aging,
since the stiffness of the central elastic arteries increases to a greater ex-
tent than that of peripheral muscular arteries [2], the aortic/brachial
stiffness gradient is ﬁrst equalized (aortic stiffness = brachial artery
stiffness), and then even reverted (aortic stiffness N brachial artery stiff-
ness). This process, called aortic-brachial stiffness mismatch [3–5], has
important hemodynamic and clinical consequences since it reduces
the reﬂection waves, increasing the reﬂection site distance, causes vas-
cular damage through the enhanced transmission of forward energy
waves into the microcirculation [5], contributes to the pathogenesis of
white matter lesions of the brain [6] and renal dysfunction [7,8] and,
at least in patients with ESRD, is strongly and independently associated
with increased mortality [9].
Recently, hypothesizing that systemic inﬂammation was associated
with functional and structural arterial stiffening in patients withhts reserved.
ulcerative colitis and chronic kidney disease, Eur J InternMed (2017),
2 L. Zanoli et al. / European Journal of Internal Medicine xxx (2017) xxx–xxxinﬂammatory bowel disease (IBD) [10], we reported that aortic stiffness
was increased [11] and that the aortic stiffening was reduced by anti-
tumor necrosis factor (anti-TNF) therapy in young patients with IBD
[12]. These ﬁndings were conﬁrmed in several studies performed by in-
dependent groups, in meta-analyses performed by our group [13–15],
and in a meta-analysis performed by an independent group that,
methodologic issues aside [16], has also reported both increased
intima-media thickness and reduced ﬂow-mediated dilation in patients
with IBD [17]. These ﬁndings, coupled to the elevated risk of coronary
heart disease and cerebrovascular accident reported in patients with
IBD [18], help to explain the IBD paradox: increased cardiovascular
risk with a low prevalence of classic cardiovascular risk factors [19].
Both CKD and ulcerative colitis (UC) are characterized by an increase
of aortic stiffness [1,9,11–15,17]. However, since the causes and the
mechanisms involved in the arterial stiffening seem to be different
[10,20], also the arterial phenotype, the hemodynamic and the clinical
consequences could be different in UC and CKD. In this regard, in pa-
tients with UC and in those with rheumatoid arthritis, two models of
chronic inﬂammation, it has been reported that both elastic andmuscu-
lar arteries can stiffenwhereas only elastic (aortic) stiffness seems to be
involved in CKD [1,9,11,12,21,35]. We believe that inﬂammation pro-
duces a delayed stiffnessmismatch during aging in UC, and that a rever-
sal of the physiological stiffness gradient (mismatch), previously
reported in chronic hemodialysis patients, begins in the early stages of
CKD. Therefore, the goals of this studywere 1) to assess the extent of ar-
terial stiffening in central and peripheral arteries in patients with UC
with a minimal burden of risk factors for cardiovascular disease and in
those with stages 3–4 CKD with comparable aortic stiffness; 2) to ex-
plore the determinants of the stiffness gradient in patients with UC
and in those with CKD.
2. Materials and methods
This was a single-center cross-sectional study conducted at the De-
partment ofMedicine of theUniversity of Catania. A total of 135 subjects
was enrolled: 45 stage 3–4 CKD were matched to both 45 patients with
UC and 45 control subjects, for age, gender, heart rate, central diastolic
blood pressure (DBP) and mean blood pressure (MBP). The CKD and
UC subjects were also matched for carotid-femoral pulse wave velocity
(cf-PWV). In order to achieve a fair match, we recruited subjects with
asymptomatic hypertension and dyslipidemia as controls. Individuals
with coronary heart disease, congestive heart failure, stroke, transient
ischemic attack, intermittent claudication, diabetes and malignancies
were excluded, as were subjects being treated for hypertension with
alpha blockers, beta blockers and calcium channel blockers, and current
or previous smokers (interruption of smoking b 1 year). Written in-
formed consent was obtained from each patient included in the study.
The study protocol conforms to the ethical guidelines of the 1975 Decla-
ration of Helsinki. The study protocol had been priorly approved by the
Institution's ethics committee on research on humans.
2.1. Study design
All participants were studied in a quiet roomwith a controlled tem-
perature of 22 ± 1 °C after 15 min of recumbent rest. In each subject, a
non-invasive hemodynamic studywas performed by an expert operator
blinded to clinical data and therapy. A second operator, blinded to the
hemodynamic examination, collected the clinical data using a standard-
ized questionnaire.
2.2. Hemodynamic data
The non-invasive study of hemodynamic variableswas performed as
follows. Brachial blood pressure measurements were taken using an
oscillometric device (Dinamap ProCare 100; GE Healthcare, Milwaukee,
USA).Please cite this article as: Zanoli L, et al, Pulse wave velocity differs between
http://dx.doi.org/10.1016/j.ejim.2017.08.020The cf.-PWV and the carotid-radial pulse wave velocity (cr-PWV, in
the right arm) were measured by a SphygmoCor device (SphygmoCor
system®, AtCorMedical, Sydney, Australia) using the foot-to-foot veloc-
ity method, the intersecting tangent algorithm and the direct distance
between the measurement sites [22]: PWV (m/s) = 0.8 × [direct dis-
tance (m)/Δt]. Two consecutive recordings were performed, and, if the
difference between the two measurements was b0.5 m/s, the mean
value was used for this analysis; otherwise, a third recording was per-
formed, and the median value was used. In our laboratory, the intra-
and intersession coefﬁcients of variation of PWV are 3.1% and 6.8%, re-
spectively. The PWV ratio was calculated from the ratio between cf.-
PWV and cr-PWV (PWV ratio = cf.-PWV/cr-PWV).
To assess the central pulsewave proﬁle, the radial pulsewave proﬁle
was recorded by applanation tonometry after recalibrationwith brachi-
al systolic blood pressure (SBP) and DBP in the contralateral arm
(SphygmoCor system®, AtCor Medical, Sydney, Australia). The central
pulse wave proﬁle was constructed using the generalized transfer func-
tion, from which the central SBP, DBP, MBP, pulse pressure (PP), aug-
mentation pressure (reﬂected wave amplitude), the round trip travel
time of the forward wave from the ascending aorta to the major “effec-
tive” reﬂection site and back (Tr) and heart-rate-adjusted central aug-
mentation index (AIx@75) were derived as previously described and
validated (Fig. 1 Panel A) [23]. The distance to the major ‘effective’ site
of wave reﬂection was calculated as: distance to reﬂection site = cf.-
PWV × Tr/2.
2.3. Biological variables
Standard laboratory were measured 1–7 days before the hemody-
namic study in our centralized laboratory. The estimated GFR (eGFR)
was calculated using the CKD-EPI creatinine equation [24]. The diagno-
sis of UCwas based on established clinical, radiological, endoscopic, and
histological criteria [25]. UC severity was evaluated with the Partial
Mayo Score [26]; active disease was deﬁned by the Partial Mayo Score
≥ 2.
2.4. Statistical analysis
We determined the sample size adequate to demonstrate that pa-
tientswith CKD have a higher PWV ratio than patients with UC and con-
trol subjects. Full description of sample size calculation is reported in
Supplementary data.
Continuous variables are presented as the median (10–90 percen-
tile); categorical variables are presented as percentages. Clinical and he-
modynamic variables were compared using Kruskal-Wallis Test for
continuous variables with Dunn's test for multiple comparison and
chi-squared tests for categorical variables at univariate analyses. A
outlier-robust univariate linear regression analysis was used to evaluate
the determinants of the PWV. The Potthoff analysis was used to com-
pare regression lines.We performed a outlier-robustmultivariate linear
regression analysis of the clinical, biological and pharmacological vari-
ables that were associated with the PWV ratio in univariate linear re-
gression analyses. Z-score was calculated according to the following
formula: z-score = (individual value− population mean)/population
standard deviation, where the mean values and standard deviation
were calculated in the controls of each cohort. A two-tailed p-value b
0.05 was considered statistically signiﬁcant. Statistical analyses were
performed using NCSS 2007 & PASS 11 software (Gerry Hintze,
Kaysville, UT, USA).
3. Results
Table 1 shows the clinical variables of the patients included in this
study signiﬁcantly different between groups; the remaining clinical
data are reported in Supplementary Table 1. The matching process
showed that the UC patients, CKD patients and control subjects wereulcerative colitis and chronic kidney disease, Eur J InternMed (2017),
Fig. 1. PanelA: aortic pressurewaves.PanelB–D: distance to reﬂection site, time to reﬂection (Tr/2) and augmentation index adjusted for heart rate (AIx@75) in controls (C), patientswith
ulcerative colitis (UC) andpatientswith chronic kidney disease (CKD) grouped bypulsewave velocity (PWV) ratio. Kruskal-Wallis TestwithDunn's test formultiple comparison. ⁎p b 0.05.
AP, augmentation pressure (reﬂected wave amplitude); AIx, augmentation index; P1, early systolic pressure peak; P2, late systolic pressure peak; PP, pulse pressure; PWV, pulse wave
velocity; Tr, travel time.
Table 1
Main clinical data of the study population.
Variables Controls
(n= 45)
UC
(n= 45)
CKD
(n= 45)
p-Valuea Group's comparison⁎
Group A B C
Body mass index, kg/m2 26 (20; 36) 24 (19; 30) 25 (21; 35) 0.04 A ≠ B
GFR, mL/min/1.73m2 103 (74; 130) 102 (84; 130) 41 (16; 59) b0.001 A ≠ C; B ≠ C
WBCs, 109/L 6.3 (4.3; 7.9) 6.7 (4.5; 10.5) 6.4 (4.4; 9.6) 0.03 A ≠ B
C-reactive protein, mg/L 1.4 (1.0–3.1) 6.9 (2.2–18.4) 3.8 (3.3–6.3) b0.001 A ≠ B; A ≠ C
Neutrophils, 109/L 3.7 (2.4; 5.2) 4.4 (2.8; 7.8) 3.4 (2.4; 7.2) 0.01 A ≠ B; B ≠ C
N/L ratio 2.0 (1.3; 3.2) 2.5 (1.3; 6.3) 2.1 (1.0; 4.0) 0.03 A ≠ B; B ≠ C
Total cholesterol, mmol/L 182 (146; 213) 170 (126; 195) 199 (158; 214) b0.001 B ≠ C
LDL, mmol/L 107 (71; 144) 95 (66; 128) 126 (76; 144) b0.001 A ≠ B; B ≠ C
Plasma glucose, mg/dL 92 (80; 101) 88 (77; 102) 96 (82; 110) 0.01 B ≠ C
Peripheral PP, mm Hg 45 (32; 65) 50 (40; 65) 51 (37; 68) 0.02 A ≠ B; A ≠ C
Central PP, mm Hg 34 (20; 48) 37 (27; 53) 40 (25; 55) 0.02 A ≠ C
Distance to reﬂection site, cm 53 (44; 69) 62 (47; 81) 63 (47; 74) 0.001 A ≠ B; A ≠ C
cf-PWV, m/s 7.5 (5.6; 9.3) 8.5 (5.9; 10.2) 8.6 (6.9; 10.5) 0.001 A ≠ B; A ≠ C
cr-PWV, m/s 7.7 (6.0; 9.5) 8.7 (7.0; 10.2) 7.5 (6.1; 9.5) b0.001 A ≠ B; B ≠ C
PWV ratio 0.97 (0.74; 1.25) 0.97 (0.79; 1.20) 1.12 (0.84; 1.45) b0.001 A ≠ C
Medication
ACEi/ARB, % 27 24 33 0.62
Diuretics, % 7 4 24 0.01
Salicylates, % 22 64 27 b0.001
Steroids, % 0 33 0 b0.001
Azathioprine, % 0 20 0 b0.001
Anti TNF, % 0 22 0 b0.001
Results are median (10–90 percentile) or %.
ACEi indicates angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blockers; cf.-PWV, carotid-femoral pulsewave velocity; CKD, chronic kidney disease; cr-PWV, carotid-
radial pulse wave velocity; GFR, glomerular ﬁltration rate; LDL, low-density lipoprotein; N/L, neutrophils/lymphocytes; PP, pulse pressure; PWV, pulse wave velocity; TNF, tumor necrosis
factor; UC, ulcerative colitis; and WBCs, white blood cells.
a As appropriate, chi-square and Kruskal-Wallis tests.
⁎ Dunn's test for multiple comparisons: p b 0.05.
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based differences were reported. In patients with CKD, as expected,
central PP was signiﬁcantly higher than in controls. Patients with
UC had a lower body mass index than control subjects and lower
total cholesterol, low-density lipoprotein and plasma glucose levels
than CKD patients. C-reactive protein, white blood cells, neutrophils
and the neutrophil-to-lymphocyte ratio were signiﬁcantly higher in
patients with UC.
According to the study design, theUCandCKDpatientswere compa-
rable in terms of cf.-PWV. However, cr-PWV was higher in UC patients
than in control subjects and CKD patients (median 8.7, 7.7 and
7.5 m/s, respectively; p b 0.001). Consequently, the PWV ratio was
higher in CKD patients than in controls and UC patients (median 1.12,
0.97 and 0.97, respectively; p b 0.001).3.1. Hemodynamic variables and stiffness mismatch
Main hemodynamic variables in individualswith normal (PWV ratio
b 1) and reverted stiffness gradient (PWV ratio ≥ 1) is reported in Fig. 1
Panel B-D. The distance to reﬂection site was increased whereas the
time to reﬂection (Tr/2, Fig. 1 Panel A) remains almost unchanged in pa-
tients with UC and CKD with reverted stiffness gradient. Respect to pa-
tients with CKD, in those with UC the distance to reﬂection was
increased in presence of normal stiffness gradient and comparable in
presence of reverted stiffness. Salicylates dose varies from 100 mg/die
in controls and patients with CKD to 1600–4000 mg/die in patients
with UC.Fig. 2. Panel A, Association between carotid femoral pulse wave velocity (cf-PWV) and carotid
patients with chronic kidney disease (CKD). Panel B–D, association between age and pulse wav
controls, patientswith ulcerative colitis (UC) and chronic kidney disease (CKD). Potthoff analysi
(p b 0.001); **PWV ratio increased substantiallymorewith age in patientswith CKD than in thos
than in those with CKD (p= 0.01).
Please cite this article as: Zanoli L, et al, Pulse wave velocity differs between
http://dx.doi.org/10.1016/j.ejim.2017.08.0203.2. Association between aortic and brachial stiffness
In Fig. 2 Panel A is reported the association between cf.-PWV and cr-
PWV. Brachial stiffness (cr-PWV) increased substantially more with
aortic stiffening (cf-PWV) in patients with UC than in those with CKD
(Potthoff analysis: p= 0.001).3.3. Determinants of the PWV ratio
Despite the PWV ratio being positively associated with age in all
groups (Fig. 2 Panel B), the PWV ratio increased more by aging in pa-
tients with CKD than in those with UC (Potthoff analysis: p = 0.01).
This was mostly explained by the higher increase of cr-PWV by aging
in patientswithUC than in thosewith CKD(Fig. 2 Panel D; Potthoff anal-
ysis: p= 0.01).
In patients with UC, the PWV ratio increased according to disease
duration, C-reactive protein and active disease (Fig. 3 Panel A–C). In
multivariate linear regression analysis, the PWV ratio was positively as-
sociated with age and, alternatively, C-reactive protein or active disease
(Table 2).
In patients with CKD, the PWV ratio increased according to the se-
verity of renal dysfunction from stage 3A CKD to stage 4 CKD (p b
0.001; Fig. 4 Panel A); this increase was largely due to the increase in
cf.-PWV (p b 0.001; Fig. 4 Panel B) and the parallel lack of increase in
cr-PWV by CKD stage (p= 0.99; Fig. 4 Panel C). In multivariate linear
regression analysis, the PWV ratio was positively associated with age
and GFR (Table 2).-radial pulse wave velocity (cr-PWV) in controls, patients with ulcerative colitis (UC) and
e velocity (PWV) ratio, carotid-femoral PWV (cf-PWV) or carotid-radial PWV (cr-PWV) in
s: *cr-PWV increased substantiallymorewith cf.-PWV in controls than in patientswith CKD
ewithUC (p=0.01); ***cr-PWV increased substantiallymorewith age inpatientswithUC
ulcerative colitis and chronic kidney disease, Eur J InternMed (2017),
Fig. 3.Association between pulsewave velocity (PWV) ratio and C-reactive protein (Panel
A), disease duration (Panel B), or active disease (Panel C) in patients with ulcerative
colitis.
Table 2
Multivariate analysis. Clinical and biochemical determinants of the PWV ratio.
Determinants of PWV
ratio
z-score Beta p-Value Model
R2
Controls
Age, 10 years 0.55 (0.32; 0.79) 0.06 (0.04; 0.09) b0.001 0.346
UC
Model A
Age, 10 years 0.32 (0.07; 0.57) 0.04 (0.01; 0.06) 0.01 0.301
C-reactive protein,
10 mg/L
0.08 (0.02; 0.14) 0.04 (0.01; 0.07) 0.01
Model B
Age, 10 years 0.35 (0.11; 0.59) 0.04 (0.01; 0.06) 0.01 0.279
Active disease, yes 0.43 (0.003;
0.857)
0.08 (0.001;
0.150)
0.048
CKD
Age, 10 years 0.76 (0.39; 1.14) 0.08 (0.04; 0.12) b0.001 0.518
GFR, 15 mL/min/1.73
m2
−0.56 (−1.05;
−0.07)
−0.07 (−0.13;
−0.01)
0.02
Outlier-robust multivariate linear regressions show the variables that were signiﬁcantly
associated with the PWV ratio. CKD indicates chronic kidney disease; GFR, glomerular ﬁl-
tration rate; PWV, pulse wave velocity; UC, ulcerative colitis.
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4.1. Arterial phenotype in patients with UC
The arterial phenotype of patientswith UCwas different from that of
patients with CKD and control subjects. Indeed, for comparable aortic
stiffness, brachial stiffness was signiﬁcantly higher in UC than in CKD
patients and control subjects. Also, the carotid remodeling seems to be
different between IBD and CKD since in previous studies intima-mediaPlease cite this article as: Zanoli L, et al, Pulse wave velocity differs between
http://dx.doi.org/10.1016/j.ejim.2017.08.020thickness was higher in patients with IBD than in controls, but it was
not increased in those with CKD during a follow-up of 3 years [17,27].
During the last years, it has been reported that severalmarkers of in-
ﬂammation are associated with increased arterial stiffness. The associa-
tion between disease duration, a variable associated with chronic
inﬂammation, and increased arterial stiffness in patients with UC is in
accordance with previous data [11,12,28,29]; the association between
acute inﬂammation and arterial stiffening has been previously reported
in other models of inﬂammation [30]. Taken together, these ﬁndings
suggest that, in contrast to physiological aging and accelerated aging re-
ported in patients with CKD, in whom aortic, but not brachial stiffening
was shown, in UC patients both elastic andmuscular components of ar-
terial tree could be affected by inﬂammation. Although the hypothesis
of a different arterial phenotype in patients with high-grade inﬂamma-
tionmust be conﬁrmed in prospective studies, data of the present study
are in agreement with previous observations in patients with IBD [11,
12] and in those with rheumatoid arthritis, in whom an increase in elas-
tic artery stiffness and a trend toward a muscular artery stiffening were
observed [21]. Furthermore, the increase of both aortic and brachial
stiffness in patients with IBD is also in agreement with the notion that
in patients with inﬂammation arterial stiffness could be linked to re-
duced smoothmuscle cell relaxation (functional arterial stiffening) or in-
creased metalloproteinases, degradation of tissue inhibitor of matrix
metalloproteinases, increased hypertrophy/reduced apoptosis and os-
teoblast marker expression of smooth muscle cells (structural arterial
stiffening) [10]. By contrast, in CKD patients, a derangement of intrinsic
elastic properties of the arterial wall appears secondary to calciﬁcation
of elastic lamellae, increased extracellular matrix and collagen content
[20].
4.2. Accelerated vascular aging in early stages CKD
In youth, the physiological stiffness gradient (aortic stiffness
b brachial artery stiffness) helps to attenuate the transmission of the
forward pressure wave into the microcirculation. During normal aging
and ESRD, a condition characterized by accelerated vascular aging,
there is an increase of central aortic stiffness, which leads to increased
aortic PWV, earlier wave reﬂection and increased cardiac workload
and left ventricular hypertrophy [1], non-counterbalanced by an in-
crease in peripheral brachial stiffness [31–33]. Interestingly, in patients
on hemodialysis the brachial stiffness can be also reducedwhen the aor-
tic stiffness is increased [10]. This mechanism, reducing the backward
wave reﬂections, could be seen as an attempt to mitigate the effects of
increased central aortic stiffness on central blood pressure. However,
it is also potentially deleterious for the peripheral target organs, becauseulcerative colitis and chronic kidney disease, Eur J InternMed (2017),
Fig. 4. Pulse wave velocity (PWV) ratio (Panel A), carotid-femoral PWV (cf-PWV) (Panel
B) and carotid-radial PWV (cr-PWV) (Panel C) in controls and in patients with chronic
kidney disease (CKD) classiﬁed according to the stage of CKD. Kruskal-Wallis Test with
Dunn's test for multiple comparison. *p b 0.05 vs. controls and CKD stage 3A.
6 L. Zanoli et al. / European Journal of Internal Medicine xxx (2017) xxx–xxxit increases the transmission of forward waves to the microcirculation.
This may help to explainwhy the stiffnessmismatch is amore powerful
prognostic indicator ofmortality than aortic stiffness, central pulse pres-
sure, pulse pressure ampliﬁcation or augmentation index in hemodialy-
sis patients [9].
In accordancewith a previous report [34], we demonstrated that the
distance to reﬂection site was higher in patients with UC and thosewithPlease cite this article as: Zanoli L, et al, Pulse wave velocity differs between
http://dx.doi.org/10.1016/j.ejim.2017.08.020CKD with a reversed aortic-brachial arterial stiffness gradient (Fig. 1
Panel B). Interestingly, the time to reﬂection was comparable in UC
and CKD patients with stiffness mismatch (Fig. 1 Panel C), suggesting
that the greater travel distancewas counterbalanced by increased aortic
stiffness. Moreover, the stiffness mismatchwas associated with a great-
er Aix@75 (Fig. 1 Panel D) in patients with UC, indicating an increase of
wave reﬂections, left ventricular afterload and myocardial oxygen
demand.4.3. Methodological issues
This study has some limitations. First, it is a cross-sectional study;
therefore, causation cannot be determined for any of the observed rela-
tionships. Moreover, whether the brachial stiffening in UC patients is
the result of a change in elastic properties of the arterial wall or of a
change in the wall-to-lumen ratio remains unknown. Finally, the rela-
tively small sample size and the cross-sectional design did not allow
to evaluate the effect of antihypertensive and immunosuppressive
drugs on the elastic/muscular artery stiffness gradient. Further to the
present proof of concept study, future larger prospective surveys are
necessary to explore these issues.4.4. Perspectives
Current guidelines underline the importance of aortic stiffening in
the pathogenesis and risk prediction of cardiovascular diseases. Howev-
er, the importance of the central elastic/peripheralmuscular artery stiff-
ness gradient in the pathogenesis of cardiovascular diseases is currently
understated. Considering that the stiffness mismatch increases the
transmission of the forward pressure wave into the microcirculation,
it could be of interest to assess whether the arterial phenotype of pa-
tients with UC, characterized by an increase of elastic and muscular ar-
tery stiffness, either protects from or, otherwise, enhances
microcirculation damage. In this regard, both endothelial dysfunction
and microcirculation damage have been previously reported in UC pa-
tients [17,36], and can by themselves contribute to the progression of
vascular dysfunction in UC.
Finally, IBD represents a model in which the effects of inﬂammation
on arterial stiffening, and the development of cardiovascular diseases,
can be studied in the presence of a low prevalence of traditional cardio-
vascular risk factors.5. Conclusions
The arterial phenotype of UC is different from that of CKD. In patients
with UC, the stiffness of both elastic and muscular arteries is increased
likely as a consequence of inﬂammation. Moreover, in patients with
CKD the stiffness mismatch starts earlier, namely from stage 3B CKD.Conﬂict of interest
The Authors declare that there is no conﬂict of interest.Funding
This study was partially supported by the Ministry of Health, Italy
(GR-2011-02349066).
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